425 related articles for article (PubMed ID: 21916573)
1. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Cibula D; Zikan M; Dusek L; Majek O
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
[TBL] [Abstract][Full Text] [Related]
3. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
5. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
6. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
7. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
10. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
11. Body weight and risk of breast cancer in BRCA1/2 mutation carriers.
Manders P; Pijpe A; Hooning MJ; Kluijt I; Vasen HF; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer H; Ausems MG; van Os TA; Gomez-Garcia EB; Brohet RM; ; van Leeuwen FE; Rookus MA
Breast Cancer Res Treat; 2011 Feb; 126(1):193-202. PubMed ID: 20730487
[TBL] [Abstract][Full Text] [Related]
12. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
13. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
15. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
16. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
17. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
18. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
19. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]